Overview

The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19

Status:
Completed

Trial end date:
2022-02-24

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy and tolerability of TADIOS compared to placebo in patients with mild to moderate COVID-19.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Helixmith Co., Ltd.